Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.37 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159104 | 0.81 | HCAR3 (0.49) | PTGS2TP53TSHRSRD5A2 | |
| SCHEMBL1857270 | 0.79 | PTGS2 (0.50) | PTGS2TP53TSHRCA12CA1 | |
| SCHEMBL4436629 | 0.77 | OPRD1 (0.45) | TSHRSRD5A2 | |
| SCHEMBL1504586 | 0.74 | ALDH1A1 (0.48) | PTGS2 | |
| SCHEMBL28133765 | 0.74 | TSHR (0.46) | PTGS2TP53TSHRSRD5A2DDAH1 | |
| SCHEMBL3169976 | 0.73 | TSHR (0.37) | PTGS2TP53TSHRSRD5A2DDAH1 | |
| SCHEMBL3168535 | 0.73 | BRD4 (0.40) | PTGS2TP53TSHRBCL2L1BAD | |
| SCHEMBL3174187 | 0.71 | IDH1 (0.50) | TP53TSHRSRD5A2DDAH1CA12 | |
| SCHEMBL24849980 | 0.70 | HTR3A (0.36) | PTGS2 | |
| SCHEMBL480137 | 0.69 | CREBBP (0.58) | TP53TSHRSRD5A2DDAH1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | claimed |
| CN-1684954-A | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2005-10-19 | — | — | CN | claimed |
| EP-1546133-A2 | N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | claimed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | claimed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | claimed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | claimed |
| EP-3423451-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| CN-103906733-A | TRMP8 antagonists and their use in treatments | AMGEN INC | 2014-07-02 | — | — | CN | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-7138525-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| CN-1684954-A | N-substituted-2-oxodihydropyridine derivative | BANYU PHARMA CO LTD (JP) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546133-A2 | N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6869966-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | PTGS2 711/4885TP53 4604/4885TSHR 2647/4885 |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | NPY1R, NPY2R, NPY4R | PTGS2 687/4885TP53 4867/4885TSHR 139/4885 |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | GPR119, NPY4R, NPY1R | PTGS2 2861/4885TP53 4854/4885TSHR 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.